Regeneron Pharmaceuticals, Inc. $(REGN)$ and Sanofi recently announced results from the DISCOVER Phase 4, single-arm, open-label trial of Dupixent® (dupilumab) in adults and adolescents with moderate-to-severe atopic dermatitis with skin of color. The results were presented at the 2025 Revolutionizing Atopic Dermatitis $(RAD)$ Conference. This trial marks the first clinical investigation of Dupixent in a large population with darker skin tones. Findings demonstrated significant improvements in disease severity, with 76% of participants achieving a 75% or greater improvement. Notable reductions in hyperpigmentation, dry skin, and itch were also observed. The safety profile was consistent with existing data, and the trial supports a commitment to advancing the understanding of chronic diseases in communities of color.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.